Patient Preparation and Care

Radiopharmaceutical is the cornerstone of nuclear medicine, referring to a compound that combines a radioactive isotope with a biologically active molecule. Understanding its composition, half‑life, and mechanism of action is essential for safe patient preparation. For example, technetium‑99m sestamibi is used in myocardial perfusion imaging; the carrier molecule (sestamibi) targets myocardial cells, while technetium‑99m provides the gamma emissions detected by the camera. The choice of radiopharmaceutical determines the required fasting period, hydration protocol, and specific contraindications.

The term administered activity describes the amount of radioactivity, measured in megabecquerels (MBq) or millicuries (mCi), that is injected or ingested by the patient. Accurate calculation of administered activity follows the principle of ALARA – as low as reasonably achievable – balancing diagnostic image quality with radiation exposure. For instance, a pediatric thyroid scan may require a lower administered activity than an adult bone scan, necessitating adjustments based on patient weight and the specific isotope’s decay characteristics.

Dosage differs from administered activity in that dosage often refers to the therapeutic intent, such as in radioiodine treatment for hyperthyroidism. While diagnostic procedures aim for the minimum activity to achieve adequate counts, therapeutic procedures may use higher activities to deliver a therapeutic radiation dose to target tissues. The distinction is vital when counseling patients about expected side effects and post‑procedure precautions.

Patient consent is a legal and ethical requirement before any nuclear medicine procedure. The consent process must include an explanation of the radiopharmaceutical’s purpose, potential risks, radiation safety measures, and alternatives. Documentation should be signed and dated, and a copy provided to the patient. Informed consent also encompasses specific considerations for vulnerable populations, such as pregnant women, lactating mothers, and individuals with impaired decision‑making capacity.

Pregnancy screening is mandatory for all women of childbearing potential. A thorough history, combined with a pregnancy test when appropriate, helps identify early gestation, which may contraindicate certain radiopharmaceuticals due to fetal radiation exposure. For example, iodinated isotopes can cross the placenta and affect fetal thyroid development. In such cases, alternative imaging modalities like ultrasound or MRI may be recommended.

Lactation considerations involve assessing the potential transfer of radioactivity into breast milk. For isotopes that are excreted in milk, guidelines often suggest temporary cessation of breastfeeding, with expressed milk discarded for a defined period. The duration depends on the isotope’s half‑life and the amount of activity administered. For instance, after a iodine‑131 therapy, breastfeeding may be suspended for up to 6–8 weeks, whereas a low‑dose technetium‑99m injection may only require a few hours of interruption.

Fasting requirements vary based on the radiopharmaceutical’s pharmacokinetics. Some agents, such as fluorodeoxyglucose (FDG), require a minimum of 4–6 hours of fasting to reduce serum glucose levels and improve myocardial uptake. Others, like bone‑seeking agents, have no fasting restrictions but may benefit from a light meal to avoid nausea. Clear instructions should be provided in writing, specifying the duration and any permissible fluids (e.g., water).

Hydration protocol is essential for many nuclear medicine procedures to facilitate renal clearance of the radiopharmaceutical and reduce radiation dose to the bladder wall. Patients are typically advised to drink 500 mL to 1 L of water before and after the scan, unless contraindicated by cardiac or renal disease. Adequate hydration also helps prevent artifacts caused by residual activity in the urinary tract.

Thyroid blocking is employed when using iodine‑based radiopharmaceuticals to prevent unwanted uptake by the thyroid gland. Administration of stable iodine (e.g., potassium iodide) prior to the scan saturates the thyroid’s iodine transport mechanisms, reducing radiation dose to the gland. The timing of the block (usually 1–2 hours before injection) and the dosage must be tailored to the specific isotope and patient’s thyroid status.

Premedication may be necessary for patients with known hypersensitivity to certain radiopharmaceutical components. Antihistamines or corticosteroids can be administered prophylactically to mitigate allergic reactions. For example, a patient with a documented allergy to sodium pertechnetate may receive a low‑dose antihistamine before a technetium‑99m scan. Documentation of the reaction and the pre‑medication regimen should be recorded in the patient’s chart.

Sedation is rarely required in nuclear medicine but may be indicated for claustrophobic or pediatric patients who cannot remain still. The choice of sedative agent, dosing, and monitoring must comply with institutional policies and involve a qualified anesthesiologist or sedation nurse. Post‑procedure observation is crucial to ensure patient safety until the sedative effects have fully resolved.

Positioning and immobilization devices ensure reproducible and high‑quality images. Standard positioning includes supine, prone, or upright orientations, depending on the organ of interest. Immobilization tools such as vacuum cushions, foam pads, and straps help maintain patient stability, especially during longer acquisition times. Proper positioning reduces motion artifacts and improves diagnostic confidence.

Shielding protects both the patient and staff from unnecessary radiation exposure. Lead aprons, thyroid shields, and protective barriers are employed during injection and while the patient is in the scanner. For example, a technologist may stand behind a lead shield while the patient is positioned in a gamma camera to minimize scatter exposure.

Radiation safety protocols encompass the entire workflow, from radiopharmacy preparation to patient discharge. Key concepts include time, distance, and shielding. Minimizing the time spent near the patient, maximizing distance, and using appropriate shielding collectively reduce occupational dose. Personal dosimeters are worn by staff to monitor cumulative exposure, and dose records are reviewed regularly to ensure compliance with regulatory limits.

Image acquisition parameters are integral to patient preparation. Adjustments to matrix size, collimator selection, and acquisition time are made based on the administered activity and the patient’s body habitus. For instance, a larger patient may require longer acquisition times or a high‑sensitivity collimator to achieve sufficient count statistics.

Quality control procedures verify that the imaging system is functioning correctly before patient exposure. Daily tests include uniformity checks, energy calibration, and detector stability assessments. Any deviation from established tolerances must be addressed before proceeding with patient imaging to avoid compromised diagnostic information.

Contrast agents are occasionally used in conjunction with nuclear medicine studies, such as in hybrid SPECT/CT or PET/CT examinations. The timing and dosage of iodinated or gadolinium‑based contrast must be coordinated with the radiopharmaceutical injection to prevent interference with tracer distribution. For example, a contrast‑enhanced CT performed after a PET scan should be scheduled to avoid overlap of high background activity.

Patient education is a pivotal component of preparation. Clear, jargon‑free explanations about the procedure, expected sensations, and post‑procedure precautions enhance compliance and reduce anxiety. Visual aids, such as diagrams of the scanner and flowcharts of the appointment timeline, can be employed to reinforce verbal instructions.

Post‑procedure precautions vary according to the radionuclide’s physical properties and the organ system targeted. General recommendations may include maintaining hydration, limiting close contact with vulnerable individuals (e.g., infants, pregnant partners) for a prescribed period, and avoiding high‑intensity physical activity that could increase organ uptake. Specific guidance for iodine‑131 therapy, for instance, includes a low‑iodine diet for 2 weeks and avoiding crowded public transportation for several days.

Radiation exposure limits for patients are defined by regulatory bodies. Diagnostic procedures typically result in effective doses ranging from 1 to 10 mSv, whereas therapeutic doses can be several hundred mSv. Communicating these values in relatable terms (e.g., equivalent to a cross‑country flight) helps patients contextualize the risk.

Biokinetic models predict the distribution and clearance of radiopharmaceuticals within the body. Understanding these models assists clinicians in scheduling imaging at optimal times post‑injection, known as the “uptake phase.” For FDG, the standard uptake time is 60 minutes, allowing sufficient accumulation in metabolically active tissues while background activity declines.

Contraindications are specific conditions that preclude the use of certain radiopharmaceuticals. Absolute contraindications may include severe renal impairment for agents cleared renally, or known hypersensitivity to the tracer’s components. Relative contraindications, such as uncontrolled diabetes for FDG imaging, require individualized risk‑benefit analysis.

Patient positioning aids such as laser alignment tools ensure that the region of interest is centered within the field of view. Accurate alignment reduces the need for repeat scans, conserving both radiopharmaceutical and patient time. Staff should verify alignment using anatomical landmarks before initiating acquisition.

Motion artifacts can degrade image quality and obscure pathology. Strategies to mitigate motion include patient coaching, comfortable positioning, and, when necessary, respiratory gating or breath‑hold techniques. For example, a cardiac SPECT study may employ a gating system that synchronizes image acquisition with the patient’s ECG to produce motion‑free reconstructions.

Allergy documentation is essential for safe radiopharmaceutical administration. Any prior reaction, even if mild, should be recorded in the patient’s electronic health record and flagged for future procedures. This practice enables pre‑emptive measures such as antihistamine pre‑medication or selection of alternative agents.

Medication review prior to imaging identifies drugs that may interfere with tracer uptake. Certain medications, like beta‑blockers, can reduce myocardial FDG uptake, while others, such as metformin, may increase bowel activity and obscure abdominal lesions. A comprehensive medication list allows the clinician to advise temporary discontinuation or substitution when appropriate.

Blood glucose monitoring is a critical step before FDG PET scans. Target glucose levels are typically below 150 mg/dL (8.3 mmol/L) to ensure optimal myocardial and tumor uptake. Elevated glucose competes with FDG for cellular transport, potentially leading to false‑negative results. Patients with diabetes may require rescheduling or insulin adjustment under medical supervision.

Radiopharmaceutical preparation occurs under aseptic conditions in the radiopharmacy. The process includes generator elution, labeling, quality control, and sterile filtration. The final product must meet sterility, pyrogenicity, and radiochemical purity specifications before release for patient administration. Documentation of each step provides traceability and compliance with Good Manufacturing Practice (GMP) standards.

Injection technique influences the distribution of the radiopharmaceutical. Intravenous injections should be performed using a sterile catheter and proper flushing to prevent residual activity in the tubing. For oral or inhalation routes, patient instruction on proper technique is essential to avoid spillage and ensure consistent dosing.

Time‑activity curves plot the radiopharmaceutical’s concentration within a target organ over time. These curves guide optimal imaging windows and help assess therapeutic efficacy. In radioiodine therapy for thyroid cancer, serial measurements of thyroid uptake at 24 hours and 48 hours post‑dose inform dosimetry calculations.

Dosimetry quantifies the absorbed radiation dose by specific organs. Personalized dosimetry, using patient‑specific imaging data, enhances safety by tailoring administered activity to the individual’s physiological characteristics. For example, in peptide receptor radionuclide therapy (PRRT), dosimetry helps avoid renal toxicity by adjusting cumulative activity.

Radiation protection signage directs staff and patients to designated areas and indicates controlled zones. Proper signage is mandatory to enforce safety zones, especially during high‑dose procedures. Signs must be clearly visible, standardized, and placed at entry points to the radiopharmacy, injection rooms, and imaging suites.

Patient discharge instructions are provided after the procedure, summarizing post‑procedure precautions, contact information, and emergency guidelines. Instructions may include a schedule for follow‑up imaging, dietary recommendations, and signs of adverse reactions that warrant immediate medical attention. Written handouts complement verbal counseling and serve as a reference for patients at home.

Emergency procedures for radiopharmaceutical spills or accidental exposure are outlined in institutional protocols. Immediate containment, decontamination, and reporting are required. Staff should be trained in the use of spill kits, absorbent materials, and protective equipment to minimize contamination and radiation dose.

Regulatory compliance involves adherence to national and international standards governing the use of radioactive materials. Agencies such as the Nuclear Regulatory Commission (NRC) in the United States or the European Atomic Energy Community (Euratom) set limits on occupational exposure, waste disposal, and transport of radiopharmaceuticals. Continuous monitoring and periodic audits ensure ongoing compliance.

Waste management for radioactive materials includes segregation of contaminated supplies, decay storage, and proper disposal. Sharps, syringes, and IV sets used during injection must be placed in designated biohazard containers with radiation labeling. Waste decay periods are calculated based on the isotope’s half‑life, after which materials can be disposed of as non‑radioactive waste.

Patient comfort is a key consideration throughout the nuclear medicine workflow. Maintaining a comfortable room temperature, providing blankets, and offering music or visual distraction can reduce anxiety. For pediatric patients, child‑friendly décor and the presence of a parent or caregiver can improve cooperation and reduce motion.

Communication with referring physicians ensures that imaging protocols align with clinical questions. Detailed requisitions specifying the indication, suspected pathology, and required anatomical coverage guide technologists in selecting appropriate radiopharmaceuticals and imaging parameters. Feedback loops between the nuclear medicine team and referring clinicians promote continuous quality improvement.

Documentation standards require comprehensive recording of all steps: patient identification, consent, radiopharmaceutical details (batch number, activity, expiry), injection site, time of administration, and any adverse events. Accurate documentation facilitates traceability, legal protection, and audit readiness.

Patient identification verification employs a dual‑check system, often using two identifiers (e.g., name and date of birth) to prevent wrong‑patient errors. Bar‑code scanning of the patient’s wristband and the radiopharmaceutical vial adds an electronic safety layer, reducing the risk of mismatched administrations.

Scheduling logistics balance the radiopharmaceutical’s physical decay with patient flow. Short‑half‑life isotopes, such as fluorine‑18 (110 minutes), require tight coordination between the cyclotron, radiopharmacy, and imaging suite to minimize delays. Effective scheduling mitigates waste and ensures that patients receive the intended activity.

Radiopharmaceutical transport follows strict regulations for the safe movement of radioactive substances. Packaging must meet shielded container standards, and transport documentation includes activity, isotope, and destination. Temperature control may be needed for certain agents to preserve stability.

Patient positioning for hybrid imaging (SPECT/CT or PET/CT) involves aligning the functional and anatomical components. The patient is first positioned for the CT scan, then the gamma camera or PET detector acquires the functional data without moving the patient. This approach reduces misregistration errors and improves fusion accuracy.

Attenuation correction compensates for photon loss due to tissue absorption, enhancing image uniformity. In CT‑based attenuation correction, the CT data provide a map of tissue density, which is applied to the nuclear medicine images. Proper positioning and breath‑hold techniques are essential to avoid mismatches between the CT and emission data.

Scatter correction removes photons that have changed direction, which can degrade image contrast. Software algorithms model scatter distributions based on detector geometry and patient size. Accurate scatter correction contributes to quantitative reliability, especially in dosimetry calculations.

Partial volume effect refers to the underestimation of activity in small lesions due to limited spatial resolution. Recognizing this effect is important when interpreting low‑count lesions, as it may necessitate higher administered activity or advanced reconstruction techniques to improve detectability.

Reconstruction algorithms such as ordered‑subset expectation maximization (OSEM) and filtered back projection (FBP) transform raw projection data into cross‑sectional images. The choice of algorithm influences noise levels, resolution, and quantitative accuracy. Advanced iterative methods often provide better image quality but require longer processing times.

Standardized uptake value (SUV) is a semi‑quantitative metric used in PET imaging to compare tracer uptake across patients or lesions. Calculating SUV involves normalizing the measured activity concentration to the injected dose and patient body weight (or lean body mass). Understanding SUV limitations, such as dependence on timing and blood glucose, is crucial for accurate interpretation.

Radiation dose reporting to patients includes the effective dose and organ‑specific doses. Providing this information in lay terms helps patients make informed decisions and alleviates concerns about radiation risks. For example, stating that a bone scan delivers a dose comparable to a few months of natural background radiation contextualizes the exposure.

Patient follow‑up after therapeutic procedures includes monitoring for delayed side effects, such as hypothyroidism after iodine‑131 therapy. Periodic laboratory tests (e.g., thyroid function tests) and imaging assessments are scheduled according to protocol, ensuring early detection of complications and timely intervention.

Training and competency assessment for staff involved in patient preparation and care is mandated by accreditation bodies. Competency checks include hands‑on evaluation of injection technique, radiation safety practices, and emergency response. Ongoing education updates personnel on evolving guidelines and emerging radiopharmaceuticals.

Psychosocial support recognizes that patients may experience anxiety related to radiation exposure, procedural discomfort, or disease diagnosis. Providing access to counseling services, patient support groups, and clear communication can improve overall patient experience and adherence to preparation instructions.

Special populations such as the elderly, children, and patients with disabilities require tailored preparation strategies. For pediatric patients, weight‑based dosing and child‑friendly explanations are essential. For frail elderly patients, attention to mobility, fall risk, and comorbidities guides positioning and monitoring.

Case example: myocardial perfusion imaging illustrates many preparation concepts. A 58‑year‑old male with known coronary artery disease is scheduled for a stress‑rest technetium‑99m sestamibi scan. He is instructed to fast for 4 hours, hydrate with 500 mL of water, and avoid caffeine for 24 hours. His medication list includes beta‑blockers, which are temporarily withheld under physician guidance to avoid blunted stress response. After injection, he is monitored for allergic reaction, remains seated for 15 minutes, and then proceeds to the imaging suite. Post‑procedure, he receives discharge instructions emphasizing continued hydration and avoidance of close contact with pregnant relatives for 24 hours.

Case example: FDG PET/CT for oncology demonstrates fasting, glucose monitoring, and radiation safety. A 45‑year‑old female with suspected lymphoma is instructed to fast for 6 hours, drink only water, and maintain blood glucose below 150 mg/dL. She is advised to discontinue metformin 48 hours prior to avoid increased bowel uptake. After confirming glucose level at 110 mg/dL, a 370 MBq dose of FDG is administered intravenously. The patient rests quietly for 60 minutes, then undergoes a low‑dose CT for attenuation correction followed by PET acquisition. Post‑scan, she is counseled on radiation precautions, including limiting prolonged close contact with infants for 24 hours.

Challenges in patient preparation often arise from non‑adherence to fasting or hydration instructions, leading to suboptimal image quality. Strategies to overcome this include reminder calls, clear written materials, and flexible scheduling to accommodate patient needs. In emergent cases, such as acute pulmonary embolism evaluation with ventilation‑perfusion scanning, fasting may be waived, but rapid assessment of contraindications becomes paramount.

Inter‑disciplinary collaboration enhances patient care. Radiopharmacists, technologists, nurses, physicians, and medical physicists each contribute expertise. For instance, the radiopharmacist ensures the radiopharmaceutical meets quality standards; the technologist oversees injection and positioning; the nurse monitors vitals and manages sedation; the physician interprets images; and the physicist validates dosimetry and quality control. Regular multidisciplinary meetings foster communication and resolve workflow bottlenecks.

Documentation of adverse events such as nausea, vomiting, or skin reactions provides valuable data for quality improvement. Reporting systems capture the severity, onset time, and management steps, enabling trend analysis and protocol refinement. For example, a series of mild allergic reactions to a specific iodine‑based agent may prompt a review of pre‑medication policies.

Regulatory updates can introduce new labeling requirements, dose limits, or waste disposal guidelines. Staying current through continuing education, professional society newsletters, and regulatory bulletins ensures that patient preparation practices remain compliant and safe.

Technology advancements such as digital PET detectors and time‑of‑flight (TOF) imaging impact preparation protocols. Higher sensitivity may allow reduced administered activity, decreasing radiation burden while preserving image quality. However, staff must be trained on new acquisition parameters and potential changes in patient positioning.

Radiopharmaceutical stability is influenced by factors such as temperature, pH, and time from preparation to administration. Some agents, like gallium‑68 labeled peptides, have limited shelf life (<2 hours) and require rapid patient turnover. Stability concerns dictate that preparation and injection be coordinated closely, and that any remaining activity be accounted for in waste management.

Patient privacy must be protected throughout the preparation and imaging process. Confidential handling of consent forms, medical histories, and imaging results complies with privacy regulations such as HIPAA. Secure storage and limited access to patient records safeguard personal information.

Infection control is essential, particularly when using intravenous injection. Sterile technique, hand hygiene, and use of single‑use supplies prevent iatrogenic infections. Patients with compromised immune systems may require additional precautions, such as prophylactic antibiotics or dedicated injection rooms.

Radiation exposure to family members is a common concern. Providing clear guidance on safe distances, sleeping arrangements, and hygiene practices (e.g., washing hands after voiding) helps alleviate anxiety. In most cases, exposure to household members remains well below recommended limits, but documentation of calculated dose estimates can be reassuring.

Monitoring vital signs during and after radiopharmaceutical administration detects early signs of adverse reactions. Blood pressure, heart rate, and oxygen saturation are recorded at baseline, during injection, and at regular intervals thereafter. Any abnormal findings trigger immediate medical evaluation.

Special considerations for renal impairment affect the clearance of many radiopharmaceuticals. For patients with reduced glomerular filtration rate (GFR), dose reduction or alternative agents with hepatic clearance may be necessary. Pre‑procedure assessment of renal function via serum creatinine and estimated GFR informs these decisions.

Hepatic function assessment is similarly important for agents metabolized by the liver, such as hepatobiliary iminodiacetic acid (HIDA) scans. Elevated bilirubin or transaminases may alter tracer uptake patterns, necessitating adjusted imaging timing or alternative diagnostic strategies.

Pregnancy‑related imaging alternatives include ultrasound, MRI, and low‑dose CT when appropriate. When nuclear medicine is essential, selecting the lowest effective activity and employing rigorous shielding reduces fetal dose. In selected cases, PET/MRI may provide functional information with reduced radiation compared to PET/CT.

Breastfeeding interruption timelines are isotope‑specific. For technetium‑99m agents, a brief interruption (e.g., 4–6 hours) may suffice, whereas for iodine‑131, a longer cessation (up to several weeks) is required. Providing lactating patients with a clear schedule and support resources, such as donor milk options, facilitates compliance.

Patient transport within the facility must consider radiation safety. Escorting the patient from the injection room to the imaging suite should follow designated low‑traffic routes, and staff may wear personal dosimeters. In some institutions, a mobile lead shield is used to protect personnel during transport.

Environmental controls in the imaging suite, such as temperature and lighting, affect patient comfort and tracer distribution. Maintaining a stable ambient temperature prevents vasoconstriction, which could alter peripheral tracer uptake. Dim lighting may reduce patient anxiety during prolonged scans.

Documentation of radiopharmaceutical batch includes lot number, expiration date, and calibration factor. This traceability is critical for recall procedures and for correlating any adverse events with a specific batch. Batch records are retained according to regulatory retention periods, often spanning several years.

Radiation dose monitoring for staff involves periodic review of dosimeter readings. If a staff member’s cumulative dose approaches regulatory limits, administrative actions such as task rotation or additional shielding are implemented to reduce exposure.

Patient feedback mechanisms collect information on the preparation experience, clarity of instructions, and overall satisfaction. Analyzing this feedback identifies areas for improvement, such as simplifying consent forms or enhancing pre‑procedure communication.

Standard operating procedures (SOPs) encapsulate all steps of patient preparation, from scheduling to discharge. SOPs are reviewed annually, incorporating new evidence, technology updates, and regulatory changes. Adherence to SOPs ensures consistency across staff and shifts.

Radiation incident reporting is mandated for any unintended exposure beyond prescribed limits. Prompt reporting, root‑cause analysis, and corrective actions mitigate future risks. Incident logs are reviewed by the radiation safety committee to track trends and implement system‑wide safeguards.

Ethical considerations include balancing diagnostic benefit against radiation risk, especially in vulnerable populations. Shared decision‑making, where patients are actively involved in weighing options, respects autonomy and aligns care with patient values.

Future directions in patient preparation may involve personalized protocols based on genomics, metabolic profiling, and artificial intelligence‑driven scheduling. Predictive models could forecast optimal uptake times, adjust hydration recommendations, and anticipate potential adverse reactions, further refining the patient experience.

In summary, mastery of the terminology and concepts related to patient preparation and care is essential for professionals managing nuclear medicine services. Thorough knowledge of radiopharmaceutical characteristics, safety protocols, patient education, and interdisciplinary coordination ensures high‑quality imaging, patient safety, and regulatory compliance. Continuous learning and adaptation to emerging technologies will sustain excellence in this rapidly evolving field.